Portal de Periódicos da CAPES

Reply from Dr. Ohtsuka to Interferon‐alpha for the treatment of severe entero‐ and neuro‐Behçet's disease

2015; Wiley; Volume: 42; Issue: 2 Linguagem: Inglês

10.1111/1346-8138.12716

1346-8138

Tsutomu Ohtsuka,

IgG4-Related and Inflammatory Diseases

The Journal of DermatologyVolume 42, Issue 2 p. 230-230 Letter to the Editor Reply from Dr. Ohtsuka to Interferon-alpha for the treatment of severe entero- and neuro-Behçet's disease Tsutomu Ohtsuka, Corresponding Author Tsutomu Ohtsuka Department of Dermatology, International University of Health and Welfare Hospital, Tochigi, JapanCorrespondence: Tsutomu Ohtsuka, M.D., Ph.D., Department of Dermatology, International University of Health and Welfare Hospital, 537-3 Iguchi Nasushiobara, Tochigi 329-2763, Japan. Email: [email protected]Search for more papers by this author Tsutomu Ohtsuka, Corresponding Author Tsutomu Ohtsuka Department of Dermatology, International University of Health and Welfare Hospital, Tochigi, JapanCorrespondence: Tsutomu Ohtsuka, M.D., Ph.D., Department of Dermatology, International University of Health and Welfare Hospital, 537-3 Iguchi Nasushiobara, Tochigi 329-2763, Japan. Email: [email protected]Search for more papers by this author First published: 27 January 2015 https://doi.org/10.1111/1346-8138.12716Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Chroni E, Monastirli A, Polychronopoulos P et al. Epileptic seizures as the sole manifestation of neuro-Behcet's disease: complete control under interferon-alpha treatment. Seizure 2008; 17: 744–747. 2Monastirli A, Chroni E, Georgiou S et al. Interferon-a treatment for acute myelitis and intestinal involvement in severe Behcet's Disease. QJM 2010; 103: 787–790. 3Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis 2014; 5: 112–134. 4Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61–70. 5Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785–796. Volume42, Issue2February 2015Pages 230-230 ReferencesRelatedInformation